Research News for 2008
-
Russian and Chinese Studies Question Breast Self-Exam
Breast self-exam doesn't seem to reduce the risk of dying from breast cancer and may cause unnecessary biopsies.
-
Removing Ovaries with Uterus Doesn’t Seem to Offer Health Benefits
Removing the ovaries at the same time as hysterectomy has both benefits and risks that need to be considered before surgery.
-
Malignant Stem Cells Seem to Make HER2-Positive Cancers Grow
HER2-positive breast cancers seem to have a large number of abnormal stem cells, which make the cancers grow and spread.
-
Research Finds Common Genes in Breast Cancer in Younger Women
Breast cancers diagnosed in younger women seem to have a large group of genes in common.
-
Women Whose Breasts Look Different from Each Other After Lumpectomy More Likely to Feel Bad
Women whose breasts look significantly different from each other after lumpectomy are more likely to be depressed and feel ashamed of their bodies.
-
New HER2 Tested Approved in U.S.
The U.S. Food and Drug Administration (FDA) has approved a new test to determine if a breast cancer is HER2-positive.
-
Molecular Breast Imaging Has Promise
A small study found that molecular breast imaging was similar to breast MRI in detecting breast cancer. Molecular breast imaging costs much less than breast MRI and is easier to interpret than breast MRI.
-
Bariatric Surgery Seems to Reduce Risk
A Canadian study found that people who had weight-loss surgery for severe obesity had a reduction in their overall cancer risk by 80% in the 5 years after the surgery.
-
Actonel Boosts Bone Health After Chemo
Actonel (chemical name: risendronate), a bone-strengthening medicine, can improve bone health after chemotherapy for breast cancer. Actonel can also lessen the bone weakening that sometimes happens when hormonal therapy is used after chemotherapy.
-
Scientists Discover Compound That Blocks Breast Cancer Growth Signals
Researchers have discovered a substance called TPBM that blocks the gene signals that tell an estrogen receptor-positive breast cancer cell to grow once estrogen binds to the receptors. TPBM blocks those signals even in ER-positive cancer cells resistant to tamoxifen.
